H M Mohan1, E Ryan1, I Balasubramanian2, R Kennelly2, R Geraghty2, F Sclafani2, D Fennelly2, R McDermott2, E J Ryan1, D O'Donoghue2, J M P Hyland2, S T Martin2, P R O'Connell1, D Gibbons2, Des Winter1, K Sheahan3. 1. Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland; School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland. 2. Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. 3. Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland; School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland. Electronic address: k.sheahan@st-vincents.ie.
Abstract
BACKGROUND: Up to 15% of colorectal cancers exhibit microsatellite instability (MSI), where errors in replication go unchecked due to defects in the mismatch repair system. This study aimed to determine survival in a large single-centre series of 1250 consecutive colorectal cancers subjected to universal MSI testing. METHODS: Clinical and pathological features of patients with colorectal cancer identified on prospectively maintained colorectal and pathology databases at St. Vincent's University Hospital from 2004 to May 2012 were examined. Mismatch repair (MMR) status was determined by immunohistochemistry. Kaplan-Meier curves, the log-rank test and Cox regression were used to associate survival with clinical and pathological characteristics. RESULTS: Of the 1250 colorectal cancers in the study period, 11% exhibited MSI (n = 138). Patients with MSI tumours had significantly lower rates of lymph node and distant metastases (MSI N+ rate: 24.8% compared with MSS N+ rate: 46.2%, p < 0.001). For Stage I and II disease MSI was associated with improved disease free survival (DSS) compared with MSS colon cancer. However, patients with Stage III MSI colon cancers had a worse DSS than those with MSS tumours. Stage III MSI tumours exhibited higher rates of lymphovascular invasion and perineural invasion than Stage I/II MSI tumours. CONCLUSION: MSI is associated with a reduced risk of nodal and distant metastases, with an improved DSS in Stage I/II colon cancer. However, when MSI tumours progress to Stage III these patients had worse outcomes and pathological features. New strategies for this cohort of patients may be required to improve outcomes.
BACKGROUND: Up to 15% of colorectal cancers exhibit microsatellite instability (MSI), where errors in replication go unchecked due to defects in the mismatch repair system. This study aimed to determine survival in a large single-centre series of 1250 consecutive colorectal cancers subjected to universal MSI testing. METHODS: Clinical and pathological features of patients with colorectal cancer identified on prospectively maintained colorectal and pathology databases at St. Vincent's University Hospital from 2004 to May 2012 were examined. Mismatch repair (MMR) status was determined by immunohistochemistry. Kaplan-Meier curves, the log-rank test and Cox regression were used to associate survival with clinical and pathological characteristics. RESULTS: Of the 1250 colorectal cancers in the study period, 11% exhibited MSI (n = 138). Patients with MSI tumours had significantly lower rates of lymph node and distant metastases (MSI N+ rate: 24.8% compared with MSS N+ rate: 46.2%, p < 0.001). For Stage I and II disease MSI was associated with improved disease free survival (DSS) compared with MSS colon cancer. However, patients with Stage III MSI colon cancers had a worse DSS than those with MSS tumours. Stage III MSI tumours exhibited higher rates of lymphovascular invasion and perineural invasion than Stage I/II MSI tumours. CONCLUSION: MSI is associated with a reduced risk of nodal and distant metastases, with an improved DSS in Stage I/II colon cancer. However, when MSI tumours progress to Stage III these patients had worse outcomes and pathological features. New strategies for this cohort of patients may be required to improve outcomes.
Authors: Grainne M O'Kane; Éanna Ryan; Terri P McVeigh; Ben Creavin; John Mp Hyland; Diarmuid P O'Donoghue; Denise Keegan; Robert Geraghty; Delia Flannery; Carmel Nolan; Emily Donovan; Brian J Mehigan; Paul McCormick; Cian Muldoon; Michael Farrell; Conor Shields; Niall Mulligan; Michael John Kennedy; Andrew J Green; Desmond C Winter; Padraic MacMathuna; Kieran Sheahan; David J Gallagher Journal: Cancer Med Date: 2017-05-03 Impact factor: 4.452
Authors: É J Ryan; B Creavin; Y L Khaw; M E Kelly; H M Mohan; R Geraghty; E J Ryan; R Kennelly; A Hanly; S T Martin; D Fennelly; R McDermott; D Gibbons; P R O'Connell; K Sheahan; D C Winter Journal: BJS Open Date: 2018-07-24
Authors: Fee Klupp; Christina Giese; Niels Halama; Clemens Franz; Felix Lasitschka; Arne Warth; Thomas Schmidt; Matthias Kloor; Alexis Ulrich; Martin Schneider Journal: Cancer Manag Res Date: 2019-02-22 Impact factor: 3.989
Authors: Aya Alsayed; Salem E Salem; Mostafa M El Serafi; Mona S Abdellateif; Abdel-Rahman N Zekri; Marwa Mohanad; Abeer A Bahnassy Journal: Onco Targets Ther Date: 2021-03-16 Impact factor: 4.147
Authors: Douglas J Hartman; Madison Frank; Lindsey Seigh; Haroon Choudry; James Pingpank; Matthew Holtzman; David Bartlett; Nathan Bahary; Liron Pantanowitz; Reetesh K Pai Journal: Am J Surg Pathol Date: 2020-07 Impact factor: 6.298